Background/Aims
The diagnosis of functional heartburn is important for management, however it stands on fragile pH monitoring variables, ie, acid exposure time varies from day to day and symptoms are often few or absent. Aim of this study was to investigate consistency of the diagnosis of functional heartburn in subsequent days using prolonged wireless pH monitoring and its impact on patients’ outcome.
Methods
Fifty proton pump inhibitotor refractory patients (11 male, 48 years [range, 38–57 years]) with a diagnosis of functional heart-burn according to Rome III in the first 24 hours of wireless pH monitoring were reviewed. pH variables were analysed in the following 24-hour periods to determine if tracings were indicative of diagnosis of non-erosive reflux disease (either acid exposure time > 5% or normal acid exposure time and symptom index ≥ 50%). Outcome was assessed by review of hospital files and/or telephone interview.
Results
Fifteen out of 50 patients had a pathological acid exposure time after the first day of monitoring (10 in the second day and 5 in subsequent days), which changed their diagnosis from functional heartburn to non-erosive reflux disease. Fifty-four percent of non-erosive reflux disease vs 11% of functional heartburn patients (
P
< 0.003) increased the dose of proton pump inhibitors or underwent fundoplication after the pH test. Outcome was positive in 77% of non-erosive reflux disease vs 43% of functional heartburn patients (
P
< 0.05).
Conclusions
One-third of patients classified as functional heartburn at 24-hour pH-monitoring can be re-classified as non-erosive reflux disease after a more prolonged pH recording period. This observation has a positive impact on patients’ management.
Background/aimsInvestigation of gastro-oesophageal reflux disease is usually performed off proton pump inhibitors (PPIs). This can exacerbate symptoms, potentially impacting investigation accuracy if patients circumvent the preinvestigation instructions. There are no standard recommendations on how to manage PPI withdrawal. We aimed to assess the impact of structured alginate use on symptom burden.MethodsParticipants were already established on ≥4 weeks of PPI therapy and being referred for manometry and 24-hour pH/impedance testing. Preinvestigation instructions involved stopping PPIs and H2 receptor antagonists for 1 week, but antacids and alginates were allowed until the night before. Participants were randomised to follow these standard instructions (control group), or the same instructions with the provision of Gaviscon Advance to be taken four times daily (treatment group). The primary outcome assessed change in Gastro-Oesophageal Reflux Disease Health-Related Quality of Life Score.Key resultsData for 48 patients were available for primary outcome assessment. While patients in the control group had a significant increase in symptoms (median difference 6.5, 95% CI (1 to 7), p=0.04), no change occurred in the treatment arm (median difference -1.5, 95% CI (-2, 3.5), p=0.54). There were no serious adverse events.ConclusionsStructured alginate use prevents symptom exacerbation during preinvestigation PPI wash-out. These findings are limited to the 1-week wash-out period but can benefit thousands of patients undergoing investigation for gastro-oesophageal reflux each year. Further research is required to assess this effect in other settings, such as sustained PPI deprescription. The trial was funded by Reckitt Benckiser.Trial registration numberEudraCT registration 2019-004561-41
Background
Prior to antireflux surgery, most patients with symptoms of gastroesophageal reflux disease (GERD) have been taking long-term proton pump inhibitors (PPIs). PPIs have been shown to cause changes to the intestinal microbiota, such as small intestinal bacterial overgrowth (SIBO), which is characterised by symptoms of gas bloating. Patients undergoing antireflux surgery are not routinely screened for SIBO, yet many patients experience gas-related symptoms postoperatively.
Methods
Data from consecutive patients (n = 104) referred to a speciality reflux centre were retrospectively assessed. Patients underwent a routine diagnostic workup for GERD including history, endoscopy, oesophageal manometry and 24-h pH-impedance monitoring off PPIs. Intestinal dysbiosis was determined by hydrogen and methane breath testing with a hydrogen-positive result indicative of SIBO and a methane-positive result indicative of intestinal methanogen overgrowth (IMO).
Results
60.6% of patients had intestinal dysbiosis (39.4% had SIBO and 35.6% had IMO). Patients with dysbiosis were more likely to report bloating (74.6% vs 48.8%; P = 0.01) and belching (60.3% vs 34.1%; P = 0.01). The oesophageal acid exposure time and number of reflux episodes were similar between dysbiosis and non-dysbiosis groups, but patients with dysbiosis were more likely to have a positive reflux-symptom association (76.2% vs 31.7%; P < 0.001), especially for regurgitation in those with SIBO (P = 0.01). Hydrogen gas production was significantly greater in patients with a positive reflux-symptom association for regurgitation (228.8 ppm vs 129.1 ppm, P = 0.004) and belching (mean AUC 214.8 ppm vs 135.9 ppm, P = 0.02).
Conclusions
The prevalence of intestinal dysbiosis is high in patients with GERD, and these patients are more likely to report gas-related symptoms prior to antireflux surgery. Independently, SIBO may be a contributory factor to refractory reflux symptoms and gas bloating in antireflux surgery candidates.
Methods Data collection spanned 16 months (1/1/2016-30/4/ 2017) with 442 patients being identified from the Infoflex endoscopy database. Patients were enrolled if the main indication for upper gastrointestinal endoscopy was coded as 'Barrett's surveillance'. Review of histology reports, Infoflex accounts and clinical notes allowed acquisition of both 'Prague Classification' and 'Seattle Biopsy Protocol' data, alongside operator status (generalist or specialist). The relationship between type of endoscopy and compliance to techniques were assessed statistically through chi-squared independence testing. Results From 442 cases (Mean 66.2 years (Range 24-88)), compliance to both 'Prague Classification' and 'Seattle Biopsy Protocol' were 73% (322/442) and 70% (309/442), respectively. Access to specialist endoscopy was improved at 41% compared to 26% (2014)(2015). Furthermore, specialist endoscopy yielded superior adherence to both, 'Prague Classification' (87%, (157/181) v 63%, (165/261); X 2 =31.04, p<0.0001)) and 'Seattle Biopsy Protocol' (75%, (136/181) v 66%, (173/261); X 2 =4.09, p=0.0432)), compared with generalist counterparts. Conclusions Specialist endoscopy improves adherence to BSG recommendations. The introduction of dedicated specialist lists at this large teaching hospital will help to optimise surveillance further. Ultimately, future work is necessary to help identify whether this specialist service carries value for both, BO screening and outcomes related to oesophageal dysplasia and OAC.
Introduction Conventionally, patients with irritable bowel syndrome (IBS) are divided into subgroups based on their predominant stool pattern, either diarrhoea, constipation, or mixed stool form. However, factors other than gastrointestinal symptoms, such as psychological co-morbidities, are also highly relevant to IBS symptomatology. We explored alternative approaches to subgrouping people with IBS by incorporating factors beyond stool form alone. Methods We collected demographic, symptom, mood, and psychological health data from 1375 adult subjects in the UK community who self-identified as having IBS, and identified two cohorts meeting either the Rome III or the Rome IV diagnostic criteria. In each cohort, we performed latent class analysis, a method of cluster modelling, to identify specific subgroups (clusters) within the data. We used the Bayesian information criterion (BIC) to determine the preferred model;
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.